Petlife Financial Statements From 2010 to 2025
| PTLF Stock | USD 0.0001 0.00 0.00% |
Check Petlife Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Petlife Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Petlife financial statements analysis is a perfect complement when working with Petlife Pharmaceuticals Valuation or Volatility modules.
Petlife |
Petlife Pharmaceuticals Company Return On Asset Analysis
Petlife Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Petlife Pharmaceuticals Return On Asset | -13.62 |
Most of Petlife Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Petlife Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Petlife Pharmaceuticals has a Return On Asset of -13.6217. This is 55.68% higher than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is notably higher than that of the company.
Petlife Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Petlife Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Petlife Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Petlife Pharmaceuticals competition to find correlations between indicators driving Petlife Pharmaceuticals's intrinsic value. More Info.Petlife Pharmaceuticals is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Petlife Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Petlife Pharmaceuticals Financial Statements
Petlife Pharmaceuticals stakeholders use historical fundamental indicators, such as Petlife Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Petlife Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Petlife Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Petlife Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Petlife Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California. Petlife Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Petlife Pink Sheet
Petlife Pharmaceuticals financial ratios help investors to determine whether Petlife Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Petlife with respect to the benefits of owning Petlife Pharmaceuticals security.